Charly Chahwan

Chief Scientific Officer SyntheX

Seminars

Thursday 18th September 2025
Panel Discussion: Delving into Strategies to Achieve Selective Targeting of NRAS & HRAS Mutations for Successfully Treating a Wide Array of Cancers
2:30 pm
  • What preclinical evidence is there which showcases the potential for NRAS-targeting programs?
  • How to selectively target NRAS and minimize off-target effects?
  • How to develop a successful patient stratification strategy and clinical trial design for RAS-mutant cancer programs?
Tuesday 16th September 2025
Chair’s Opening Remarks
8:50 am
Tuesday 16th September 2025
Chair’s Closing Remarks & End of Focus Day
4:45 pm
Charly Chahwan, Co-Founder & Chief Scientific Officer, SyntheX